Literature DB >> 3180402

Myocardial reperfusion injury. Role of myocardial hypoxanthine and xanthine in free radical-mediated reperfusion injury.

A S Abd-Elfattah1, M E Jessen, J Lekven, N E Doherty, L A Brunsting, A S Wechsler.   

Abstract

The aim of this study was to differentiate myocardial reperfusion injury from that of ischemia. We assessed the role of the myocardial adenosine 5'-triphosphate (ATP) catabolites, hypoxanthine and xanthine, generated during ischemia and the early phase of reperfusion, in reperfusion injury by modulating adenosine transport and metabolism with specific metabolic inhibitors. This was followed by intracoronary infusion of exogenous hypoxanthine and xanthine. Twenty-four dogs instrumented with minor-axis piezoelectric crystals and intraventricular pressure transducers were subjected to 30 minutes of normothermic global myocardial ischemia and 60 minutes of reperfusion. In Group 1 (n = 7), normal saline was infused into the cardiopulmonary bypass reservior before ischemia and before reperfusion. Saline solution containing 25 microM p-nitrobenzylthioinosine (NBMPR) and 100 microM erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA) was infused in Group 2 (n = 10) dogs. Group 3 (n = 7) dogs were treated exactly like those in Group 2 except, at the end of the ischemic period and immediately before releasing the cross-clamp, a solution of EHNA-NBMPR containing 100 microM hypoxanthine and 100 microM xanthine was infused into the aortic root. Left ventricular performance and myocardial adenine nucleotide pool intermediates were determined before and after ischemia. ATP was depleted by about 50% (p less than 0.05 vs. preischemia) in all groups after 30 minutes of ischemia. Inosine was the major ATP catabolite (9.29 +/- 1.2 nmol/mg protein) in Group 1, while adenosine (9.91 +/- 0.7 nmol/mg protein) was the major metabolite in EHNA-NBMPR-treated dogs (Groups 2 and 3). Hypoxanthine levels were fivefold more in Group 1 compared with Groups 2 and 3 (p less than 0.05). Left ventricular performance in Group 1 decreased from 76.8 +/- 7.6 to 42.9 +/- 9.8 and 52.3 +/- 8.4 dynes/cm2 x 10(3) (p less than 0.05), while myocardial ATP decreased from 30.9 +/- 2.2 to 17.2 +/- 1.0 and 16.5 +/- 1.0 nmol/mg protein during 30 and 60 minutes of reperfusion, respectively (p less than 0.05 vs. preischemia). Ventricular function in Group 2 dogs completely recovered within 30 minutes of reperfusion, and myocardial ATP recovered to the preischemic level at 60 minutes of reperfusion. In Group 3, left ventricular performance was depressed by 39% and 30% during 30 and 60 minutes of reperfusion (p less than 0.05), respectively, and myocardial ATP did not recover during reperfusion despite a significant intramyocardial adenosine accumulation.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3180402

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  15 in total

1.  Differential cardioprotection with selective inhibitors of adenosine metabolism and transport: role of purine release in ischemic and reperfusion injury.

Authors:  A S Abd-Elfattah; M E Jessen; J Lekven; A S Wechsler
Journal:  Mol Cell Biochem       Date:  1998-03       Impact factor: 3.396

2.  Role of nucleoside transport and purine release in a rabbit model of myocardial stunning.

Authors:  A S Abd-Elfattah; R P Maddox; M E Jessen; I M Rebeyka; A S Wechsler
Journal:  Mol Cell Biochem       Date:  1998-03       Impact factor: 3.396

3.  Identification of nucleoside transport binding sites in the human myocardium.

Authors:  A S Abd-Elfattah; J Hoehner; A S Wechsler
Journal:  Mol Cell Biochem       Date:  1998-03       Impact factor: 3.396

4.  On-pump inhibition of es-ENT1 nucleoside transporter and adenosine deaminase during aortic crossclamping entraps intracellular adenosine and protects against reperfusion injury: role of adenosine A1 receptor.

Authors:  Anwar Saad Abd-Elfattah; Mai Ding; Michael E Jessen; Andrew S Wechsler
Journal:  J Thorac Cardiovasc Surg       Date:  2012-02-09       Impact factor: 5.209

5.  Myocardial protection in beating heart cardiac surgery: I: pre- or postconditioning with inhibition of es-ENT1 nucleoside transporter and adenosine deaminase attenuates post-MI reperfusion-mediated ventricular fibrillation and regional contractile dysfunction.

Authors:  Anwar Saad Abd-Elfattah; Hamdy Aly; Scott Hanan; Andrew S Wechsler
Journal:  J Thorac Cardiovasc Surg       Date:  2012-02-11       Impact factor: 5.209

6.  Hypoxanthine is a pharmacodynamic marker of ischemic brain edema modified by glibenclamide.

Authors:  Hannah J Irvine; Animesh Acharjee; Zoe Wolcott; Zsuzsanna Ament; H E Hinson; Bradley J Molyneaux; J Marc Simard; Kevin N Sheth; W Taylor Kimberly
Journal:  Cell Rep Med       Date:  2022-06-13

7.  Hot shot induction and reperfusion with a specific blocker of the es-ENT1 nucleoside transporter before and after hypothermic cardioplegia abolishes myocardial stunning in acutely ischemic hearts despite metabolic derangement: hot shot drug delivery before hypothermic cardioplegia.

Authors:  Anwar Saad Abd-Elfattah; Gert E Tuchy; Michael E Jessen; David R Salter; Jacques P Goldstein; Louis A Brunsting; Andrew S Wechsler
Journal:  J Thorac Cardiovasc Surg       Date:  2013-02-17       Impact factor: 5.209

Review 8.  Role of adenosine in the treatment of myocardial stunning.

Authors:  M B Forman; C E Velasco
Journal:  Cardiovasc Drugs Ther       Date:  1991-10       Impact factor: 3.727

9.  Nucleoside transporter subtype expression and function in rat skeletal muscle microvascular endothelial cells.

Authors:  Richard G E Archer; Václav Pitelka; James R Hammond
Journal:  Br J Pharmacol       Date:  2004-08-02       Impact factor: 8.739

10.  An analysis of the myocardial transcriptome in a mouse model of cardiac dysfunction with decreased cholinergic neurotransmission.

Authors:  Ashbeel Roy; Aline Lara; Diogo Guimarães; Rita Pires; Eneas R Gomes; David E Carter; Marcus V Gomez; Silvia Guatimosim; Vania F Prado; Marco A M Prado; Robert Gros
Journal:  PLoS One       Date:  2012-06-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.